Claris Lifesciences rose 3.13% to Rs 283 at 14:20 IST on BSE after the company said that it has received the supplemental abbreviated new drug application approval for Fluconazole Injection in the United States.
The company made announcement during market hours today, 21 April 2015.
Meanwhile, the BSE Sensex was down 31.96 points, or 0.11%, to 27,854.25.
On BSE, so far 8.87 lakh shares were traded in the counter, compared with an average volume of 3.69 lakh shares in the past one quarter.
The stock hit a high of Rs 286 and a low of Rs 275.30 so far during the day. The stock had hit a record high of Rs 358 on 13 April 2015. The stock had hit a 52-week low of Rs 141.25 on 2 June 2014.
The stock had outperformed the market over the past one month till 20 April 2015, rising 8.03% compared with 1.33% fall in the Sensex. The scrip had also outperformed the market in past one quarter, gaining 49.95% as against Sensex's 3.12% decline.
The mid-cap company has an equity capital of Rs 54.57 crore. Face value per share is Rs 10.
Claris Lifesciences announced that it has received the supplemental abbreviated new drug application (ANDA) approval for Fluconazole Injection in the United States (US). Claris currently marketing Fluconazole in 2 mg/ml formulation packed in 100 ml and 200 ml PVC bags and now with the approval of supplemental ANDA, Claris is the only company to be able to sell Fluconazole in 50 ml variant in the US. By launching the variant Claris will be addressing the need of the medical fraternity.
Claris Lifesciences' consolidated net profit jumped 406.2% to Rs 89.85 crore on 25% rise in total income to Rs 209.38 crore in Q4 December 2014 over Q4 December 2013.
Claris Lifesciences is a multi-business enterprise and the holding company of Claris Injectables, a wholly-owned subsidiary dealing in Specialty Injectables business, collectively Claris; and 'Claris Otsuka', a Joint Venture with Japanese Otsuka Pharmaceutical Factory, Inc. & Mitsui & Co. for Infusion business in India & emerging markets.
Powered by Capital Market - Live News
